Amplia Therapeutics Income Statement

Financials in millions AUD. Fiscal year is April - March.

Millions AUD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Other Revenue	5.49	3.78	4.45	1.19	1.98
Revenue	5.49	3.78	4.45	1.19	1.98
Revenue Growth (YoY)	45.11%	-15.02%	274.34%	-40.02%	29.33%
Cost of Revenue	0.39	0.21	0.44	0.31	0.15
Gross Profit	5.1	3.57	4.01	0.88	1.83
Selling, General & Admin	3.49	2.67	2.6	2.2	1.64
Research & Development	9.08	7.53	5.8	4.69	3.77
Operating Expenses	12.79	10.37	8.58	7.17	5.47
Operating Income	-7.69	-6.79	-4.57	-6.29	-3.64
Interest Expense	-0.02	-0.06	-0.08	-0.05	-0
Interest & Investment Income	-	0.28	0.15	0.1	0
EBT Excluding Unusual Items	-7.71	-6.57	-4.5	-6.24	-3.64
Pretax Income	-7.71	-6.57	-4.5	-6.24	-3.64
Net Income	-7.71	-6.57	-4.5	-6.24	-3.64
Net Income to Common	-7.71	-6.57	-4.5	-6.24	-3.64
Shares Outstanding (Basic)	470	307	194	194	146
Shares Outstanding (Diluted)	470	307	194	194	146
Shares Change (YoY)	52.97%	58.35%	0.02%	33.27%	53.71%
EPS (Basic)	-0.02	-0.02	-0.02	-0.03	-0.03
EPS (Diluted)	-0.02	-0.02	-0.02	-0.03	-0.03
Free Cash Flow	-8.77	-6.89	-5.13	-5.31	-4.42
Free Cash Flow Per Share	-0.02	-0.02	-0.03	-0.03	-0.03
Gross Margin	92.98%	94.44%	90.07%	74.14%	92.20%
Operating Margin	-140.06%	-179.51%	-102.64%	-528.45%	-183.72%
Profit Margin	-140.38%	-173.69%	-101.14%	-524.80%	-183.74%
Free Cash Flow Margin	-159.68%	-182.04%	-115.20%	-446.19%	-222.68%
EBITDA	-7.68	-6.78	-4.56	-6.28	-3.64
EBITDA Margin	-139.81%	-179.24%	-102.40%	-	-183.56%
D&A For EBITDA	0.01	0.01	0.01	0.01	0
EBIT	-7.69	-6.79	-4.57	-6.29	-3.64
EBIT Margin	-140.06%	-179.51%	-102.64%	-	-183.72%
Revenue as Reported	5.49	4.06	4.6	1.29	1.98